Xtant Medical Holdings (FRA:XMS) LT-Debt-to-Total-Asset : 0.19 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Xtant Medical Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Xtant Medical Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.19.

Xtant Medical Holdings's long-term debt to total assets ratio declined from Mar. 2023 (0.21) to Mar. 2024 (0.19). It may suggest that Xtant Medical Holdings is progressively becoming less dependent on debt to grow their business.

Xtant Medical Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Xtant Medical Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings LT-Debt-to-Total-Asset Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.81

0.03

0.23

0.18

0.20

Xtant Medical Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.27	0.17	0.20	0.19

Xtant Medical Holdings LT-Debt-to-Total-Asset Calculation

Xtant Medical Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	16.545	/	84.925
	=	0.19

Xtant Medical Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	16.163	/	86.417
	=	0.19

Xtant Medical Holdings (FRA:XMS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Xtant Medical Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (FRA:XMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (FRA:XMS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

XTNT:USA

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Xtant Medical Holdings (FRA:XMS) Headlines

No Headlines